Clinical Trials Logo

Musculoskeletal Complications clinical trials

View clinical trials related to Musculoskeletal Complications.

Filter by:

NCT ID: NCT02069340 Withdrawn - Malignant Neoplasm Clinical Trials

Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

Start date: June 2016
Phase: N/A
Study type: Interventional

This randomized clinical trial studies genetics in predicting risk of bisphosphonate-related osteonecrosis of the jaw in patients with cancer receiving zoledronic acid. Zoledronic acid is an anti-resorptive drug used as part of cancer treatment. A serious side effect of these drugs is death of the jawbone, commonly called bisphosphonate-related osteonecrosis of the jaw (BRONJ). Genetic research may help doctors understand risk factors for BRONJ or who is more likely to get BRONJ and why.

NCT ID: NCT01893892 Completed - Clinical trials for Musculoskeletal Complications

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

Start date: March 2014
Phase: N/A
Study type: Interventional

This randomized clinical trial studies levocarnitine in treating patients with vismodegib-associated muscle spasms. Levocarnitine may decrease muscle spasms caused by vismodegib.

NCT ID: NCT01824836 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Start date: June 11, 2013
Phase: N/A
Study type: Interventional

E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with AIs due to the development of musculoskeletal symptoms (MSS). Women with stage 1-111 breast cancer who are prescribed the aromatase inhibitor anastrozole as treatment may join.

NCT ID: NCT01598298 Completed - Breast Cancer Clinical Trials

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Start date: May 15, 2013
Phase: Phase 3
Study type: Interventional

RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone, and joint pain caused by hormone therapy. PURPOSE: This randomized phase III trial studies how well duloxetine hydrochloride works compared to a placebo in treating muscle, bone, and joint pain in patients with early-stage breast cancer receiving hormone therapy.

NCT ID: NCT01573442 Completed - Breast Cancer Clinical Trials

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

Start date: August 2013
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole. Testosterone may help relieve moderate or severe arthralgia associated with the use of aromatase inhibitors, such as anastrozole or letrozole.

NCT ID: NCT01371656 Completed - Diarrhea Clinical Trials

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

Start date: September 2011
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well levofloxacin works in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplant. Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy or undergoing stem cell transplant for acute leukemia. It is not yet known whether levofloxacin is effective in preventing infection.

NCT ID: NCT01097317 Recruiting - Lung Cancer Clinical Trials

First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer

Start date: September 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as carboplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemotherapy can lead to a loss of leg muscle strength. Neuromuscular electrical stimulation may improve muscle strength and quality of life. It is not yet known whether chemotherapy given together with neuromuscular electrical stimulation is more effective than chemotherapy alone in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying first-line chemotherapy given together with neuromuscular electrical stimulation to see how well it works compared with chemotherapy alone in treating patients with non-small cell lung cancer.

NCT ID: NCT00631137 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

Start date: January 2008
Phase: N/A
Study type: Interventional

RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma. PURPOSE: This randomized clinical trial is studying how well testosterone gel works in preventing weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma.

NCT ID: NCT00608738 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment

Start date: July 2001
Phase: N/A
Study type: Interventional

RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment. PURPOSE: This clinical trial is studying how well a whole-person-care guide works in identifying patient needs in patients with cancer or complications from cancer treatment.

NCT ID: NCT00602420 Completed - Pain Clinical Trials

Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

Start date: June 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Naproxen may help prevent or lessen bone pain caused by pegfilgrastim. It is not yet known whether naproxen is more effective than a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy. PURPOSE: This randomized phase III trial is studying naproxen to see how well it works compared with a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy.